NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer

Clinical trial NCT01816594 · COMPLETED

Trial details

NCT number: NCT01816594
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Newly Diagnosed, Primary Breast Cancer

Start date: 2013-09-03
Primary completion: 2015-02-18
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.